A Phase 3 interventional study of Adalimumab and Prednisone in Uveitis, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-07-07.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing adalimumab in Uveitis — 3 open to participants now, 3 under way, 1 of them phase 3. Adalimumab · Uveitis.
Among the 14 studies testing adalimumab in Uveitis, this one is the 3rd largest by enrollment, is one of 3 that started in 2010, is one of 5 in phase 3, and was the 4th registered.
300 studies on the registry are indexed under Uveitis; 33 are open to participants now.
Browse Uveitis studies →3 of the 14 studies testing adalimumab in Uveitis are open now, in 2 countries. Recruiting first, the newest first:
Hospital San Carlos, Madrid · Sites in Spain
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris
Ages 18–100
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 22 Uveitis studies recruiting now, 13 (59%) set no upper age limit and 9 (41%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 6 · Phase 4 3
First in 2006; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 261 is above the median of 30 across 175 interventional studies indexed under Uveitis.
Median enrollment 87 across the 14 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 14 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
AbbVie has 8 studies filed under Uveitis — fewer than ten, so there is no comparison to draw.
1 of the studies testing adalimumab in Uveitis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05874505Assistance Publique - Hôpitaux de Paris"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease" | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing adalimumab in Uveitis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study comparing the safety and efficacy of adalimumab compared with. placebo in adults with inactive non-infectious intermediate uveitis, posterior uveitis, or panuveitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject that for ≥ 28 days prior to the Baseline visit has inactive disease and is taking ≥ 10 mg of oral prednisone to maintain this inactive state and fulfillment of all 3 of the following criteria based on the Investigator's clinical judgment at the Screening and Baseline visits for both eyes:
Exclusion Criteria:
If entering the study on one concomitant immunosuppressive therapy, dose has not been stable for at least 28 days prior to the Baseline visit or is not within the following allowable doses at the Baseline visit:
Subject has received intravitreal anti-VEGF therapy:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received placebo subcutaneous injection at Baseline followed by every other week (eow) dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 to 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.
Drug: Prednisone · Drug: Placebo
Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses eow starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.
Drug: Adalimumab · Drug: Prednisone
Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by 40 mg eow starting at Week 1.
Also known as: ABT-D2E7, Humira
Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.
Administered by subcutaneous injection
Time to Treatment Failure on or After Week 2
Treatment failure was defined by the occurrence of a uveitis flare (the inability to maintain disease control). To be considered treatment failure, ≥ 1 of these criteria had to be present in at least 1 eye at Week 2 or all other visits: * New active, inflammatory chorioretinal, and/or inflammatory retinal vascular lesions relative to Baseline * 2-step increase relative to Baseline in anterior chamber cell grade or vitreous haze grade * Worsening of best corrected visual acuity by ≥ 15 letters relative to baseline. Time to treatment failure was analyzed using the Kaplan-Meier method. Dropouts for reasons other than treatment failure at any time during the study were censored at the drop out date. Per protocol, the primary analysis was performed in the Main Study population which included all randomized participants recruited outside Japan; for completeness results are also reported below for the Integrated dataset which includes participants recruited in Japan.
Time frame: From Baseline until end of study (up to 80 weeks)
Change in Anterior Chamber (AC) Cell Grade in Each Eye From Baseline to the Final/Early Termination Visit
Slit lamp examinations were conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam was used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: Grade 0 = \< 1 cell Grade 0.5+ = 1 - 5 cells Grade 1+ = 6 - 15 cells Grade 2+ = 16 - 25 cells Grade 3+ = 26 - 50 cells Grade 4+ = \> 50 cells.
Time frame: Baseline and at the Final/Early Termination Visit (up to 80 weeks)
Change in Vitreous Haze (VH) Grade in Each Eye From Baseline to the Final/Early Termination Visit
Vitreous haze was measured using dilated indirect ophthalmoscopy (DIO) and assessed by the Investigator according to National Eye Institute (NEI) and SUN criteria: Grade 0: No evident vitreous haze; Grade 0.5+: Slight blurring of the optic disc margin because of the haze; normal striations and reflex of the nerve fiber layer cannot be visualized; Grade 1+: Permits a better definition of both the optic nerve head and the retinal vessels (compared to higher grades); Grade 2+: Permits better visualization of the retinal vessels (compared to higher grades); Grade 3+: Permits the observer to see the optic nerve head, but the borders are quite blurry; Grade 4+: Optic nerve head is obscured.
Time frame: Baseline and Final/Early Termination Visit (up to 80 weeks)
Change In Logarithm of the Minimum Angle of Resolution (LogMAR) Best Corrected Visual Acuity (BCVA) In Each Eye From Baseline to the Final/Early Termination Visit
Using corrective lenses based on that visit's refraction testing, participant's best corrected visual acuity was measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR chart. On the logMAR scale, 0 is equivalent to 20/20 visual acuity, the range of normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment.
Time frame: Baseline and Final/Early Termination Visit (up to 80 weeks)
Time to Optimal Coherence Tomography (OCT) Evidence of Macular Edema in At Least 1 Eye On or After Week 2
Optical coherence tomography was performed at every visit using 1 of 3 approved machines. Images were evaluated by a central reader. Macular edema was defined as cystoid macular edema. OCT evidence of macular edema on or after Week 2 was to be counted as an event. Dropouts due to reasons other than OCT evidence of macular edema were to be considered as censored observations at the time of dropping out.
Time frame: From Baseline until the Final Visit (up to 80 weeks)
Percent Change in Central Retinal Thickness in Each Eye From Baseline to the Final/Early Termination Visit.
Central retinal thickness was measured using OCT and assessed by a central reader.
Time frame: Baseline and Final/Early Termination Visit (up to 80 weeks)
Change in Visual Functioning Questionnaire 25 (VFQ-25) Total Score From Baseline to the Final/Early Termination Visit
The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The overall composite score ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.
Time frame: Baseline and Final/Early Termination Visit (up 80 weeks)
Change in VFQ-25 Subscore Distance Vision From Baseline to the Final/Early Termination Visit
The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The distance vision subscore is calculated from the answers to 3 distance vision-related questions and ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.
Time frame: Baseline and Final/Early Termination Visit (up 80 weeks)
Change in VFQ-25 Subscore Near Vision From Baseline to the Final/Early Termination Visit
The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The near vision subscore is calculated from the answers to 3 near vision-related questions and ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.
Time frame: Baseline and Final/Early Termination Visit (up 80 weeks)
Change in VFQ-25 Subscore Ocular Pain From Baseline to the Final/Early Termination Visit
The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The ocular pain subscore is calculated form the answers to 2 eye pain questions and ranges from 0 to 100, where higher scores or increases in score indicate less pain.
Time frame: Baseline and Final/Early Termination Visit (up 80 weeks)
This study includes a Japan sub-study. A total of 261 adults with inactive non-infectious intermediate uveitis, posterior uveitis or panuveitis were randomized at 72 study sites worldwide; 229 participants at 62 study sites in Australia, Israel, Latin America, North America, and Europe (Main Study), and 32 participants at 10 study sites in Japan.
| Milestone | Placebo | Adalimumab |
|---|---|---|
| Started | 130 | 131 |
| Enrolled in main study | 114 | 115 |
| Enrolled in japan sub-study | 16 | 16 |
| Completed | 112 | 116 |
| Not completed | 18 | 15 |
| Withdrew: Miscellaneous | 4 | 2 |
| Withdrew: Adverse event | 7 | 11 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 |
Treatment failure was defined by the occurrence of a uveitis flare (the inability to maintain disease control). To be considered treatment failure, ≥ 1 of these criteria had to be present in at least 1 eye at Week 2 or all other visits: * New active, inflammatory chorioretinal, and/or inflammatory retinal vascular lesions relative to Baseline * 2-step increase relative to Baseline in anterior chamber cell grade or vitreous haze grade * Worsening of best corrected visual acuity by ≥ 15 letters relative to baseline. Time to treatment failure was analyzed using the Kaplan-Meier method. Dropouts for reasons other than treatment failure at any time during the study were censored at the drop out date. Per protocol, the primary analysis was performed in the Main Study population which included all randomized participants recruited outside Japan; for completeness results are also reported below for the Integrated dataset which includes participants recruited in Japan.
| months | Main Study: Placebo | Main Study: Adalimumab | Integrated Study (Main + Japan Sub-study): Placebo | Integrated Study (Main + Japan Sub-study): Adalimumab |
|---|---|---|---|---|
| Time to Treatment Failure on or After Week 2 | 8.3 (3.0 to NA) | NA (4.7 to NA) | 5.6 (2.6 to NA) | NA (3.9 to NA) |
Slit lamp examinations were conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam was used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: Grade 0 = \< 1 cell Grade 0.5+ = 1 - 5 cells Grade 1+ = 6 - 15 cells Grade 2+ = 16 - 25 cells Grade 3+ = 26 - 50 cells Grade 4+ = \> 50 cells.
| units on a scale | Main Study: Placebo | Main Study: Adalimumab | Integrated Study (Main + Japan Sub-study): Placebo | Integrated Study (Main + Japan Sub-study): Adalimumab |
|---|---|---|---|---|
| Left eye | 0.57 ± 1.001 | 0.41 ± 0.969 | 0.61 ± 1.005 | 0.46 ± 0.996 |
| Right eye | 0.53 ± 0.963 | 0.40 ± 0.927 | 0.60 ± 0.992 | 0.44 ± 0.950 |
Vitreous haze was measured using dilated indirect ophthalmoscopy (DIO) and assessed by the Investigator according to National Eye Institute (NEI) and SUN criteria: Grade 0: No evident vitreous haze; Grade 0.5+: Slight blurring of the optic disc margin because of the haze; normal striations and reflex of the nerve fiber layer cannot be visualized; Grade 1+: Permits a better definition of both the optic nerve head and the retinal vessels (compared to higher grades); Grade 2+: Permits better visualization of the retinal vessels (compared to higher grades); Grade 3+: Permits the observer to see the optic nerve head, but the borders are quite blurry; Grade 4+: Optic nerve head is obscured.
| units on a scale | Main Study: Placebo | Main Study: Adalimumab | Integrated Study (Main + Japan Sub-study): Placebo | Integrated Study (Main + Japan Sub-study): Adalimumab |
|---|---|---|---|---|
| Left eye | 0.33 ± 0.733 | 0.16 ± 0.601 | 0.35 ± 0.749 | 0.18 ± 0.614 |
| Right eye | 0.27 ± 0.605 | 0.18 ± 0.604 | 0.36 ± 0.729 | 0.18 ± 0.602 |
Using corrective lenses based on that visit's refraction testing, participant's best corrected visual acuity was measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR chart. On the logMAR scale, 0 is equivalent to 20/20 visual acuity, the range of normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment.
| logMAR | Main Study: Placebo | Main Study: Adalimumab | Integrated Study (Main + Japan Sub-study): Placebo | Integrated Study (Main + Japan Sub-study): Adalimumab |
|---|---|---|---|---|
| Left eye | 0.06 ± 0.239 | 0.01 ± 0.251 | 0.07 ± 0.230 | 0.02 ± 0.241 |
| Right eye | 0.02 ± 0.198 | -0.01 ± 0.165 | 0.04 ± 0.216 | 0.00 ± 0.169 |
Optical coherence tomography was performed at every visit using 1 of 3 approved machines. Images were evaluated by a central reader. Macular edema was defined as cystoid macular edema. OCT evidence of macular edema on or after Week 2 was to be counted as an event. Dropouts due to reasons other than OCT evidence of macular edema were to be considered as censored observations at the time of dropping out.
| months | Main Study: Placebo | Main Study: Adalimumab | Integrated Study (Main + Japan Sub-study): Placebo | Integrated Study (Main + Japan Sub-study): Adalimumab |
|---|---|---|---|---|
| Time to Optimal Coherence Tomography (OCT) Evidence of Macular Edema in At Least 1 Eye On or After Week 2 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Central retinal thickness was measured using OCT and assessed by a central reader.
| percent change | Main Study: Placebo | Main Study: Adalimumab | Integrated Study (Main + Japan Sub-study): Placebo | Integrated Study (Main + Japan Sub-study): Adalimumab |
|---|---|---|---|---|
| Left eye (N = 107, 114, 122, 130) | 6.4 ± 20.67 | 4.5 ± 29.82 | 6.3 ± 19.75 | 5.2 ± 29.91 |
| Right eye (N = 108, 113, 124, 129) | 7.7 ± 28.88 | 5.4 ± 34.83 | 9.9 ± 30.79 | 3.9 ± 33.34 |
The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The overall composite score ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.
| units on a scale | Main Study: Placebo | Main Study: Adalimumab | Integrated Study (Main + Japan Sub-study): Placebo | Integrated Study (Main + Japan Sub-study): Adalimumab |
|---|---|---|---|---|
| Change in Visual Functioning Questionnaire 25 (VFQ-25) Total Score From Baseline to the Final/Early Termination Visit | 1.24 ± 10.698 | 3.36 ± 11.73 | 1.00 ± 10.225 | 2.79 ± 12.018 |
The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The distance vision subscore is calculated from the answers to 3 distance vision-related questions and ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.
| units on a scale | Main Study: Placebo | Main Study: Adalimumab | Integrated Study (Main + Japan Sub-study): Placebo | Integrated Study (Main + Japan Sub-study): Adalimumab |
|---|---|---|---|---|
| Change in VFQ-25 Subscore Distance Vision From Baseline to the Final/Early Termination Visit | 0.76 ± 16.248 | 2.64 ± 17.165 | 0.60 ± 15.978 | 2.96 ± 17.121 |
The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The near vision subscore is calculated from the answers to 3 near vision-related questions and ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.
| units on a scale | Main Study: Placebo | Main Study: Adalimumab | Integrated Study (Main + Japan Sub-study): Placebo | Integrated Study (Main + Japan Sub-study): Adalimumab |
|---|---|---|---|---|
| Change in VFQ-25 Subscore Near Vision From Baseline to the Final/Early Termination Visit | 3.98 ± 17.397 | 3.88 ± 18.302 | 3.73 ± 17.17 | 2.89 ± 50.503 |
The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The ocular pain subscore is calculated form the answers to 2 eye pain questions and ranges from 0 to 100, where higher scores or increases in score indicate less pain.
| units on a scale | Main Study: Placebo | Main Study: Adalimumab | Integrated Study (Main + Japan Sub-study): Placebo | Integrated Study (Main + Japan Sub-study): Adalimumab |
|---|---|---|---|---|
| Change in VFQ-25 Subscore Ocular Pain From Baseline to the Final/Early Termination Visit | 2.87 ± 17.233 | 3.42 ± 21.32 | 2.60 ± 17.339 | 2.15 ± 21.689 |
Collected over From the first study drug administration until 70 days following the last study drug administration or until rollover into the extension study. Median duration of treatment was 147 days in the placebo arm and 245 days in the adalimumab arm.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 10/130 (7.7%) | 78/130 (60%) |
| Adalimumab | — | 8/131 (6.1%) | 88/131 (67.2%) |
| Event | Placebo | Adalimumab |
|---|---|---|
| DEEP VEIN THROMBOSISVascular disorders | 2/130 | 0/131 |
| CHOROIDAL NEOVASCULARISATIONEye disorders | 1/130 | 0/131 |
| RETINAL DETACHMENTEye disorders | 1/130 | 0/131 |
| SUBRETINAL FLUIDEye disorders | 1/130 | 0/131 |
| MENINGITIS ASEPTICInfections and infestations | 1/130 | 0/131 |
| TONSILLITISInfections and infestations | 1/130 | 0/131 |
| HUMERUS FRACTUREInjury, poisoning and procedural complications | 1/130 | 0/131 |
| ARTHRITISMusculoskeletal and connective tissue disorders | 1/130 | 0/131 |
| OSTEONECROSISMusculoskeletal and connective tissue disorders | 1/130 | 0/131 |
| HYPERTENSIVE CRISISVascular disorders | 1/130 | 0/131 |
| Event | Placebo | Adalimumab |
|---|---|---|
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 12/130 | 28/131 |
| NASOPHARYNGITISInfections and infestations | 20/130 | 23/131 |
| HEADACHENervous system disorders | 17/130 | 17/131 |
| FATIGUEGeneral disorders | 9/130 | 14/131 |
| URINARY TRACT INFECTIONInfections and infestations | 11/130 | 13/131 |
| COUGHRespiratory, thoracic and mediastinal disorders | 6/130 | 11/131 |
| VISUAL ACUITY REDUCEDEye disorders | 10/130 | 6/131 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 3/130 | 10/131 |
| BACK PAINMusculoskeletal and connective tissue disorders | 7/130 | 10/131 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 3/130 | 10/131 |
| Age, Continuous(years) | Placebo | Adalimumab | Total |
|---|---|---|---|
| Mean | 43.22 ± 14.026 | 43.18 ± 12.719 | 43.20 ± 13.360 |
| Age, Customized(participants) | Placebo | Adalimumab | Total |
|---|---|---|---|
| < 65 years | 121 | 125 | 246 |
| ≥ 65 years | 9 | 6 | 15 |
| Sex: Female, Male(Participants) | Placebo | Adalimumab | Total |
|---|---|---|---|
| Female | 83 | 75 | 158 |
| Male | 47 | 56 | 103 |
| Race/Ethnicity, Customized(participants) | Placebo | Adalimumab | Total |
|---|---|---|---|
| White | 96 | 96 | 192 |
| Black | 8 | 6 | 14 |
| Asian | 19 | 19 | 38 |
| American Indian/Alaskan Native | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Other | 5 | 9 | 14 |
| Multi-Race | 1 | 1 | 2 |
| Type of Uveitis(participants) | Placebo | Adalimumab | Total |
|---|---|---|---|
| Intermediate | 30 | 17 | 47 |
| Posterior | 36 | 41 | 77 |
| Panuveitis | 63 | 71 | 134 |
| Intermediate/Posterior | 1 | 2 | 3 |
| Diagnosis(participants) | Placebo | Adalimumab | Total |
|---|---|---|---|
| Idiopathic | 45 | 33 | 78 |
| Birdshot Choroidopathy | 16 | 15 | 31 |
| Multifocal Choroiditis and Panuveitis | 2 | 5 | 7 |
| Vogt Koyanagi Harada | 30 | 34 | 64 |
| Sarcoid | 20 | 22 | 42 |
| Behcet's | 7 | 10 | 17 |
| Other | 10 | 12 | 22 |
| Eye Affected(participants) | Placebo | Adalimumab | Total |
|---|---|---|---|
| Left | 3 | 3 | 6 |
| Right | 5 | 2 | 7 |
| Both | 122 | 126 | 248 |
| History of Infectious Uveitis(participants) | Placebo | Adalimumab | Total |
|---|---|---|---|
| Yes | 0 | 0 | 0 |
| No | 130 | 131 | 261 |
1 further baseline measures are reported on the registry.
No study locations are listed for this record.
The record gives a start of Aug 2010, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
AbbVie (prior sponsor, Abbott) →